Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer. Among patients with metastatic castration-resistant prostate cancer (mCRPC ...

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years. The utilization of Xtandi (enzalutamide), compared ...

Nov 3 (Reuters) - A prostate cancer drug from Medivation Inc helped patients live longer in a late-stage study, sending the company's shares soaring on hopes that it will become a strong contender in ...

The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves a combination of therapies, including chemotherapy, hormone therapy, immunotherapy, and different medications that ...

A randomized phase II trial presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium found that adding the EZH2 inhibitor mevrometostat to enzalutamide (Xtandi) ...

A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...

There’s a lot to notice from Johnson & Johnson’s earnings -- the company announced a very solid quarter. But the one thing that really stood out is the high sales that the company produced from its ...